Timo Siepmann
International University, Cambodia
14 Papers
4 Citations
Timo Siepmann is an academic researcher from International University, Cambodia. The author has contributed to research in topics: Medicine & Discontinuation. The author has an hindex of 6, co-authored 14 publications.
Chat about Author
Papers
Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease.
TL;DR: The association between the dysbiosis of Gram-negative bacteria in the gut microbiome of patients with type 2 diabetes mellitus and chronic kidney disease, increased LPS levels and the effects on inflammatory biomarkers may provide insight into potential diagnostic and therapeutic approaches in the treatment of T2DM-CKD.
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
Markus V. Heppt,Markus V. Heppt,Timo Siepmann,Jutta Engel,Gabriele Schubert-Fritschle,Renate Eckel,Laura Mirlach,Thomas Kirchner,Andreas Jung,Anja Gesierich,Thomas Ruzicka,Michael J. Flaig,Carola Berking +12 more
TL;DR: In this paper, the mutational status of BRAF and NRAS (exon 15) and exon 2 and 3 were determined in melanoma samples of 217 patients with pyrosequencing and Sanger sequencing.
Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme
Annekatrin Seidlitz,Timo Siepmann,Steffen Löck,Tareq A. Juratli,Michael Baumann,Mechthild Krause +5 more
TL;DR: Results indicate that short delays of postoperative radiochemotherapy, e.g. for screening of a patient for a clinical trial, may be uncritical and do not indicate a relevant time factor in the treatment of glioblastoma multiforme in a large contemporary single-centre cohort.
Autonomic Dysregulation in Multiple Sclerosis
TL;DR: This review summarizes the current literature on the most prevalent aspects of autonomic dysfunction in MS and provides reference to underlying pathophysiological mechanisms as well as means of diagnosis and treatment.
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
Hannah Woopen,Hannah Woopen,Rolf Richter,Fakher Ismaeel,Radoslav Chekerov,I. Roots,Timo Siepmann,Jalid Sehouli +7 more
TL;DR: As polypharmacy does not influence survival ovarian cancer patients taking several comedications may be included in clinical trials and should not be deprived of adequate cancer treatment, however, a thorough monitoring is mandatory due to the increased risk of toxicities.
35